Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{$index + 1}}. {{ watchedTerm.term }} ({{watchedTerm.accId}})
{{gene.symbol}}: {{ gene.description }}
Save what matters to you
{{ loginError }}
Sign in with your RGD account
Gene: Krtcap3 (keratinocyte associated protein 3) Rattus norvegicus
Analyze
Symbol:
Krtcap3
Name:
keratinocyte associated protein 3
RGD ID:
1596516
Description:
Predicted to localize to integral component of membrane. Orthologous to human KRTCAP3 (keratinocyte associated protein 3); INTERACTS WITH acrylamide; bisphenol A; fenvalerate.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
KCP-3; keratinocyte-associated protein 3; LOC683980; similar to keratinocytes associated protein 3
RGD Orthologs
Alliance Genes
More Info
more info ...
More Info
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 6 26,485,126 - 26,486,695 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 6 26,485,126 - 26,486,695 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 6 36,304,329 - 36,305,898 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 Celera 6 24,613,034 - 24,614,603 (-) NCBI Celera Cytogenetic Map 6 q14 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Disease Annotations - ClinVar
1,2-dimethylhydrazine multiple interactions ISO RGD:1616763 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of KRTCAP3 mRNA CTD PMID:22206623 17alpha-ethynylestradiol affects expression ISO RGD:1616763 6480464 Ethinyl Estradiol affects the expression of KRTCAP3 mRNA CTD PMID:17555576 17alpha-ethynylestradiol multiple interactions ISO RGD:1616763 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of KRTCAP3 mRNA CTD PMID:17942748 17alpha-ethynylestradiol increases expression ISO RGD:1616763 6480464 Ethinyl Estradiol results in increased expression of KRTCAP3 mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1616763 6480464 Tetrachlorodibenzodioxin affects the expression of KRTCAP3 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1616763 6480464 Tetrachlorodibenzodioxin results in increased expression of KRTCAP3 mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1616763 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of KRTCAP3 mRNA CTD PMID:17942748 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:1616763 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of KRTCAP3 mRNA CTD PMID:20188158 4,4'-diaminodiphenylmethane increases expression ISO RGD:1616763 6480464 4, 4'-diaminodiphenylmethane results in increased expression of KRTCAP3 mRNA CTD PMID:18648102 4-hydroxyphenyl retinamide increases expression ISO RGD:1616763 6480464 Fenretinide results in increased expression of KRTCAP3 mRNA CTD PMID:28973697 acrylamide affects expression EXP 6480464 Acrylamide affects the expression of KRTCAP3 mRNA CTD PMID:28959563 aflatoxin B1 decreases expression ISO RGD:1342898 6480464 Aflatoxin B1 results in decreased expression of KRTCAP3 mRNA CTD PMID:27153756 benzo[a]pyrene increases expression ISO RGD:1616763 6480464 Benzoapyrene results in increased expression of KRTCAP3 mRNA CTD PMID:22228805 benzo[a]pyrene decreases expression ISO RGD:1616763 6480464 Benzoapyrene results in decreased expression of KRTCAP3 mRNA CTD PMID:22228805 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1342898 6480464 Diethylhexyl Phthalate results in increased expression of KRTCAP3 mRNA CTD PMID:28412506 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of KRTCAP3 mRNA CTD PMID:25181051 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of KRTCAP3 gene CTD PMID:28505145 butanal decreases expression ISO RGD:1342898 6480464 butyraldehyde results in decreased expression of KRTCAP3 mRNA CTD PMID:26079696 calcitriol increases expression ISO RGD:1342898 6480464 Calcitriol results in increased expression of KRTCAP3 mRNA CTD PMID:26485663 carbamazepine affects expression ISO RGD:1342898 6480464 Carbamazepine affects the expression of KRTCAP3 mRNA CTD PMID:25979313 cyclosporin A decreases expression ISO RGD:1342898 6480464 Cyclosporine results in decreased expression of KRTCAP3 mRNA CTD PMID:27989131 dichloroacetic acid decreases expression ISO RGD:1616763 6480464 Dichloroacetic Acid results in decreased expression of KRTCAP3 mRNA CTD PMID:28962523 ethanol multiple interactions ISO RGD:1342898 6480464 [[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRTCAP3 mRNA CTD PMID:29432896 fenvalerate increases expression EXP 6480464 fenvalerate results in increased expression of KRTCAP3 mRNA CTD PMID:30307764 folic acid multiple interactions ISO RGD:1616763 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of KRTCAP3 mRNA CTD PMID:22206623 furan increases expression EXP 6480464 furan results in increased expression of KRTCAP3 mRNA CTD PMID:27387713 pentanal decreases expression ISO RGD:1342898 6480464 pentanal results in decreased expression of KRTCAP3 mRNA CTD PMID:26079696 pirinixic acid increases expression ISO RGD:1616763 6480464 pirinixic acid results in increased expression of KRTCAP3 mRNA CTD PMID:23811191 progesterone decreases expression ISO RGD:1342898 6480464 Progesterone results in decreased expression of KRTCAP3 mRNA CTD PMID:21540246 tamoxifen affects expression ISO RGD:1616763 6480464 Tamoxifen affects the expression of KRTCAP3 mRNA CTD PMID:17555576 tetraphene decreases expression ISO RGD:1616763 6480464 benzaanthracene results in decreased expression of KRTCAP3 mRNA CTD PMID:26377693 titanium dioxide increases expression ISO RGD:1616763 6480464 titanium dioxide results in increased expression of KRTCAP3 mRNA CTD PMID:23557971 valproic acid affects expression ISO RGD:1342898 6480464 Valproic Acid affects the expression of KRTCAP3 mRNA CTD PMID:25979313 valproic acid decreases expression ISO RGD:1342898 6480464 Valproic Acid results in decreased expression of KRTCAP3 mRNA CTD PMID:28001369 , PMID:29154799
References
Additional References at PubMed
Genomics
QTLs in Region (Rnor_6.0)
738023 Alc17 Alcohol consumption QTL 17 3.1 0.003 consumption behavior trait (VT:0002069) ethanol drink intake rate to body weight ratio (CMO:0001616) 6 1 35623029 Rat 1354616 Despr12 Despair related QTL 12 0.0012 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 6 1 35623029 Rat 1549905 Stresp10 Stress response QTL 10 6.83 0.0066 stress-related behavior trait (VT:0010451) number of approaches toward negative stimulus before onset of defensive burying response (CMO:0001960) 6 1 35623029 Rat 2300176 Bmd51 Bone mineral density QTL 51 11.7 0.0001 femur mineral mass (VT:0010011) bone mineral density (CMO:0001226) 6 1 35623029 Rat 2300190 Bmd52 Bone mineral density QTL 52 11.2 0.0001 femur mineral mass (VT:0010011) volumetric bone mineral density (CMO:0001553) 6 1 35623029 Rat 1331743 Uae28 Urinary albumin excretion QTL 28 4.5 urine albumin amount (VT:0002871) urine albumin level (CMO:0000130) 6 1 41917988 Rat 9589048 Scfw3 Subcutaneous fat weight QTL 3 4.57 0.001 subcutaneous adipose mass (VT:1000472) abdominal subcutaneous fat pad weight (CMO:0002069) 6 1 42388212 Rat 9589129 Insul24 Insulin level QTL 24 19.06 0.001 blood insulin amount (VT:0001560) plasma insulin level (CMO:0000342) 6 1 42388212 Rat 7411603 Foco13 Food consumption QTL 13 5.5 0.001 eating behavior trait (VT:0001431) feed conversion ratio (CMO:0001312) 6 1 42388212 Rat 7411542 Bw127 Body weight QTL 127 5.5 0.001 body mass (VT:0001259) body weight gain (CMO:0000420) 6 1 42388212 Rat 8552962 Pigfal16 Plasma insulin-like growth factor 1 level QTL 16 9.4 blood insulin-like growth factor amount (VT:0010479) plasma insulin-like growth factor 1 level (CMO:0001299) 6 1 42388212 Rat 2293709 Bss23 Bone structure and strength QTL 23 5.18 0.0001 femur morphology trait (VT:0000559) femur cross-sectional area (CMO:0001661) 6 1 43665660 Rat 2293650 Bss31 Bone structure and strength QTL 31 5.05 0.0001 femur strength trait (VT:0010010) femur midshaft polar moment of inertia (CMO:0001669) 6 1 43665660 Rat 2293656 Bss28 Bone structure and strength QTL 28 6.79 0.0001 femur morphology trait (VT:0000559) femur midshaft cortical cross-sectional area (CMO:0001663) 6 1 43665660 Rat 7411584 Foco4 Food consumption QTL 4 4.3 0.001 eating behavior trait (VT:0001431) feed conversion ratio (CMO:0001312) 6 1 44015370 Rat 738024 Sach5 Saccharine consumption QTL 5 3.9 0.00039 consumption behavior trait (VT:0002069) saccharin intake volume to total fluid intake volume ratio (CMO:0001601) 6 1 44570292 Rat 2301972 Bp325 Blood pressure QTL 325 4.8 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 6 1 75623393 Rat 1359023 Bp272 Blood pressure QTL 272 2.5 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 6 1120393 28706721 Rat 2292589 Emca10 Estrogen-induced mammary cancer QTL 10 0.048 mammary gland integrity trait (VT:0010552) post-insult time to mammary tumor formation (CMO:0000345) 6 1120393 46120393 Rat 1354664 Slep2 Serum leptin concentration QTL 2 4.49 blood leptin amount (VT:0005667) serum leptin level (CMO:0000780) 6 1120393 75023446 Rat 1576309 Emca7 Estrogen-induced mammary cancer QTL 7 4 mammary gland integrity trait (VT:0010552) mammary tumor number (CMO:0000343) 6 2537030 111715717 Rat 1578665 Bss16 Bone structure and strength QTL 16 4.4 femur morphology trait (VT:0000559) bone trabecular cross-sectional area (CMO:0002311) 6 6161722 76002731 Rat 1578668 Bmd14 Bone mineral density QTL 14 3.8 femur mineral mass (VT:0010011) total volumetric bone mineral density (CMO:0001728) 6 6161722 76002731 Rat 4145119 Mcs25 Mammary carcinoma susceptibility QTL 25 0.0001 mammary gland integrity trait (VT:0010552) ratio of deaths to total study population during a period of time (CMO:0001023) 6 7009971 115379601 Rat 634322 Bw12 Body weight QTL 12 0 body mass (VT:0001259) body weight (CMO:0000012) 7 10173862 55173862 Rat 1300128 Rf16 Renal function QTL 16 3.89 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 6 13122958 34367603 Rat 1300164 Rf15 Renal function QTL 15 3.12 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 6 13122958 57516539 Rat 10401812 Kidm54 Kidney mass QTL 54 kidney mass (VT:0002707) both kidneys wet weight (CMO:0000085) 6 16810107 61810107 Rat 10401800 Kidm49 Kidney mass QTL 49 kidney mass (VT:0002707) both kidneys wet weight (CMO:0000085) 6 16810107 61810107 Rat 8552910 Pigfal5 Plasma insulin-like growth factor 1 level QTL 5 4.3 blood insulin-like growth factor amount (VT:0010479) plasma insulin-like growth factor 1 level (CMO:0001299) 6 19417887 64417887 Rat 1641898 Colcr4 Colorectal carcinoma resistance QTL4 3.71 0.0007 intestine integrity trait (VT:0010554) well differentiated malignant colorectal tumor surface area measurement (CMO:0002077) 6 21515302 65784818 Rat 2293839 Kiddil2 Kidney dilation QTL 2 4.8 kidney pelvis morphology trait (VT:0004194) hydronephrosis severity score (CMO:0001208) 6 22042854 84763421 Rat 2293841 Kiddil4 Kidney dilation QTL 4 4.4 kidney pelvis morphology trait (VT:0004194) hydronephrosis severity score (CMO:0001208) 6 22042854 84763421 Rat